-
EP2570428
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2570428
| EP2570428 - Peptide vaccines with Seq ID No: 379 or 376 for cancers expressing tumor-associated antigens [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 13.06.2014 Database last updated on 16.11.2024 | Most recent event Tooltip | 13.06.2014 | Application deemed to be withdrawn | published on 16.07.2014 [2014/29] | Applicant(s) | For all designated states Oncotherapy Science, Inc. 2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi Kanagawa 213-0012 / JP | [2013/12] | Inventor(s) | 01 /
Tsunoda, Takuya c/o ONCOTHERAPY SCIENCE, INC. 2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi Kanagawa 213-0012 / JP | 02 /
Ohsawa, Ryuji c/o ONCOTHERAPY SCIENCE, INC. 2-1, Sakado 3-chome Takatsu-ku Kawasaki-shi Kanagawa 213-0012 / JP | [2013/12] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [N/P] |
| Former [2013/12] | Vossius & Partner Siebertstrasse 4 81675 München / DE | Application number, filing date | 12175481.6 | 21.02.2008 | [2013/12] | Priority number, date | US20070902949P | 21.02.2007 Original published format: US 902949 P | [2013/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP2570428 | Date: | 20.03.2013 | Language: | EN | [2013/12] | Type: | A3 Search report | No.: | EP2570428 | Date: | 10.07.2013 | Language: | EN | [2013/28] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 07.06.2013 | Classification | IPC: | C07K14/47, A61K39/00, A61P35/00, C07K14/745, C12N5/10, G01N33/15, G01N33/50 | [2013/12] | CPC: |
C07K14/47 (EP);
C07K7/06 (KR);
A61K38/08 (KR);
A61K39/0011 (EP,KR,US);
A61K39/001122 (EP,US);
A61K39/4611 (EP,US);
A61K39/464402 (EP,US);
A61K39/464422 (EP,US);
A61K39/464434 (EP,US);
A61K39/464462 (EP,US);
A61K39/464466 (EP,US);
A61K9/127 (KR);
A61P35/00 (EP,KR);
A61P37/04 (EP);
A61P43/00 (EP);
C07K14/4748 (EP);
C12N5/0634 (EP,KR,US);
C12N5/0638 (EP,KR,US);
G01N33/505 (KR);
A61K2039/55555 (EP,KR);
C12N2501/998 (KR);
C12N2510/00 (KR)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2013/12] | Title | German: | Peptidvakzine mit Seq ID No: 379 or 376 für tumorassoziierte Antigene exprimierenden Krebs | [2013/12] | English: | Peptide vaccines with Seq ID No: 379 or 376 for cancers expressing tumor-associated antigens | [2013/12] | French: | Vaccins de peptide avec Seq ID No: 379 or 376 pour cancers exprimant des antigènes associés aux tumeurs | [2013/12] | Examination procedure | 11.01.2014 | Application deemed to be withdrawn, date of legal effect [2014/29] | 18.02.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2014/29] | Parent application(s) Tooltip | EP08710443.6 / EP2121731 | EP12151711.4 / EP2465864 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20080710443) is 01.07.2010 | Fees paid | Renewal fee | 07.11.2012 | Renewal fee patent year 03 | 07.11.2012 | Renewal fee patent year 04 | 07.11.2012 | Renewal fee patent year 05 | 21.02.2013 | Renewal fee patent year 06 | 20.02.2014 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | |||